Evaluation of Hydra HALT-1 as a toxin moiety for recombinant immunotoxin

[1]  J. Hwang,et al.  Cytotoxic and apoptosis-inducing effects of wildtype and mutated Hydra actinoporin-like toxin 1 (HALT-1) on various cancer cell lines , 2019, PeerJ.

[2]  Adam C. Labonte,et al.  Identification of alterations in macrophage activation associated with disease activity in systemic lupus erythematosus , 2018, PloS one.

[3]  J. Kamps,et al.  Positron emission tomography (PET) and single photon emission computed tomography (SPECT) imaging of macrophages in large vessel vasculitis: Current status and future prospects. , 2018, Autoimmunity reviews.

[4]  U. Ros,et al.  Sticholysin II-mediated cytotoxicity involves the activation of regulated intracellular responses that anticipates cell death. , 2018, Biochimie.

[5]  Publisher's Note , 2018, Anaesthesia.

[6]  G. Anderluh,et al.  Pore-forming toxins in Cnidaria. , 2017, Seminars in cell & developmental biology.

[7]  T. Thepen,et al.  CD64: An Attractive Immunotherapeutic Target for M1-type Macrophage Mediated Chronic Inflammatory Diseases , 2017, Biomedicines.

[8]  P. A. Valiente,et al.  Biophysical and biochemical strategies to understand membrane binding and pore formation by sticholysins, pore-forming proteins from a sea anemone , 2017, Biophysical Reviews.

[9]  F. G. van der Goot,et al.  Damage of eukaryotic cells by the pore-forming toxin sticholysin II: Consequences of the potassium efflux. , 2017, Biochimica et biophysica acta. Biomembranes.

[10]  A. Zernecke,et al.  Macrophages in vascular inflammation and atherosclerosis , 2017, Pflügers Archiv - European Journal of Physiology.

[11]  R. Fischer,et al.  Fully human MAP‐fusion protein selectively targets and eliminates proliferating CD64+ M1 macrophages , 2016, Immunology and cell biology.

[12]  G. Anderluh,et al.  Pore formation by actinoporins, cytolysins from sea anemones. , 2016, Biochimica et biophysica acta.

[13]  A. Lurati,et al.  The macrophages in rheumatic diseases , 2016, Journal of inflammation research.

[14]  R. Fischer,et al.  Targeting CD64 mediates elimination of M1 but not M2 macrophages in vitro and in cutaneous inflammation in mice and patient biopsies , 2015, mAbs.

[15]  R. Robison,et al.  Macrophage Polarization and Its Role in Cancer , 2015 .

[16]  J. Hwang,et al.  Mutagenesis and Functional Analysis of the Pore-Forming Toxin HALT-1 from Hydra magnipapillata , 2015, Toxins.

[17]  A. Reiss,et al.  Polarization of Human THP-1 Macrophages: Link between Adenosine Receptors, Inflammation and Lipid Accumulation , 2014 .

[18]  Eliezra Glasser,et al.  Hydra actinoporin-like toxin-1, an unusual hemolysin from the nematocyst venom of Hydra magnipapillata which belongs to an extended gene family. , 2014, Toxicon : official journal of the International Society on Toxinology.

[19]  G. Melmer,et al.  Targeted ex vivo reduction of CD64‐positive monocytes in chronic myelomonocytic leukemia and acute myelomonocytic leukemia using human granzyme B‐based cytolytic fusion proteins , 2014, International journal of cancer.

[20]  Wei-Chiang Shen,et al.  Fusion protein linkers: property, design and functionality. , 2013, Advanced drug delivery reviews.

[21]  Bharat V. Adkar,et al.  Effect of Signal Peptide on Stability and Folding of Escherichia coli Thioredoxin , 2013, PloS one.

[22]  Kirsten Sandvig,et al.  Ricin and Ricin-Containing Immunotoxins: Insights into Intracellular Transport and Mechanism of action in Vitro , 2013 .

[23]  Veerendra Kumar,et al.  Linkers in the structural biology of protein–protein interactions , 2013, Protein science : a publication of the Protein Society.

[24]  S. Mayfield,et al.  Production of unique immunotoxin cancer therapeutics in algal chloroplasts , 2012, Proceedings of the National Academy of Sciences.

[25]  Yuhong Xiao,et al.  Enzyme-linked immunosorbent assay (ELISA) and blocking with bovine serum albumin (BSA)--not all BSAs are alike. , 2012, Journal of immunological methods.

[26]  Assaf Shapira,et al.  Toxin-Based Therapeutic Approaches , 2010, Toxins.

[27]  R. Fischer,et al.  Recombinant, ETA′‐based CD64 immunotoxins: improved efficacy by increased valency, both in vitro and in vivo in a chronic cutaneous inflammation model in human CD64 transgenic mice , 2010, The British journal of dermatology.

[28]  J. Lakey,et al.  A Toxin-based Probe Reveals Cytoplasmic Exposure of Golgi Sphingomyelin* , 2010, The Journal of Biological Chemistry.

[29]  R. Fischer,et al.  Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes , 2008, Molecular Cancer Therapeutics.

[30]  I. Pastan,et al.  Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity. , 2008, Cancer research.

[31]  I. Pastan,et al.  Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers , 2007, Clinical Cancer Research.

[32]  M. Harmsen,et al.  CD64-Directed Immunotoxin Inhibits Arthritis in a Novel CD64 Transgenic Rat Model1 , 2006, The Journal of Immunology.

[33]  G. Anderluh,et al.  Membrane insertion of the N-terminal α-helix of equinatoxin II, a sea anemone cytolytic toxin , 2004 .

[34]  L. Roque,et al.  Construction of an immunotoxin with the pore forming protein StI and ior C5, a monoclonal antibody against a colon cancer cell line. , 2004, International immunopharmacology.

[35]  Regina M. Krohn,et al.  Recombinant CD64-specific single chain immunotoxin exhibits specific cytotoxicity against acute myeloid leukemia cells. , 2003, Cancer research.

[36]  A. Plückthun,et al.  A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  J. Bijlsma,et al.  Selective elimination of synovial inflammatory macrophages in rheumatoid arthritis by an Fcgamma receptor I-directed immunotoxin. , 2003, Arthritis and rheumatism.

[38]  V. Gabai,et al.  Necrosis: a specific form of programmed cell death? , 2003, Experimental cell research.

[39]  Gregor Anderluh,et al.  Two-step Membrane Binding by Equinatoxin II, a Pore-forming Toxin from the Sea Anemone, Involves an Exposed Aromatic Cluster and a Flexible Helix* , 2002, The Journal of Biological Chemistry.

[40]  M. Miller,et al.  Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor. , 2000, Protein engineering.

[41]  G. Anderluh,et al.  Antiparasite activity of sea-anemone cytolysins on Giardia duodenalis and specific targeting with anti-Giardia antibodies. , 1999, International journal for parasitology.

[42]  M. Hulett,et al.  The second and third extracellular domains of FcgammaRI (CD64) confer the unique high affinity binding of IgG2a. , 1998, Molecular immunology.

[43]  R. Salmon,et al.  Escherichia coli O157 serology: false‐positive ELISA results caused by human antibodies binding to bovine serum albumin , 1998, Letters in applied microbiology.

[44]  B. Clark,et al.  Glycerol diversifies phage repertoire selections and lowers non‐specific phage absorption , 1998, FEBS letters.

[45]  J. Shaw,et al.  Cytotoxic properties of DAB486EGF and DAB389EGF, epidermal growth factor (EGF) receptor-targeted fusion toxins. , 1991, The Journal of biological chemistry.

[46]  A. Lage,et al.  A new immunotoxin built by linking a hemolytic toxin to a monoclonal antibody specific for immature T lymphocytes , 1988, International journal of cancer.

[47]  梁曉灡.  Mechanism of antibody-dependent enhancement in severe acute respiratory syndrome coronavirus infection , 2012 .

[48]  M. Comalada,et al.  Macrophage proinflammatory activation and deactivation: a question of balance. , 2010, Advances in immunology.

[49]  T. Thepen,et al.  Resolution of cutaneous inflammation after local elimination of macrophages , 2000, Nature Biotechnology.